Treatment effects of stimulant medication in young boys with fragile X syndrome (Q35680734)

9 August 2017

title

Treatment effects of stimulant medication in young boys with fragile X syndrome (English)

1 reference

9 August 2017

1 reference

Jane E Roberts

1 reference

9 August 2017

Margot Miranda

1 reference

9 August 2017

Maria Boccia

1 reference

9 August 2017

Heather Janes

1 reference

9 August 2017

Bridgette L Tonnsen

1 reference

9 August 2017

Deborah D Hatton

1 reference

9 August 2017

publication date

14 June 2011

1 reference

Journal of Neurodevelopmental Disorders

9 August 2017

published in

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

175-184

1 reference

Open-label riluzole in fragile X syndrome

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Open-label add-on treatment trial of minocycline in fragile X syndrome

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Concurrent Validity of the Child Behavior Checklist DSM-Oriented Scales: Correspondence with DSM Diagnoses and Comparison to Syndrome Scales

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Roles of fragile X mental retardation protein in dopaminergic stimulation-induced synapse-associated protein synthesis and subsequent alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) receptor internalization

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Arousal modulation in females with fragile X or Turner syndrome

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Treatment of hyperactivity in children with pervasive developmental disorders

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Practitioner review: Psychopharmacology in children and adolescents with mental retardation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Methylphenidate effects in attention deficit/hyperactivity disorder: electrodermal and ERP measures during a continuous performance task.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Psychopharmacology in fragile X syndrome--present and future

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Phenotypic variation and FMRP levels in fragile X.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Cognitive and behavioral profile of fragile X boys: correlations to molecular data

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

High functioning fragile X males: demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

The fragile-X syndrome. On the way to a behavioural phenotype

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Early developmental trajectories of males with fragile X syndrome.

12 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11689-011-9085-4

Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11689-011-9085-4

Influence of stimulants on electrodermal studies in Fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11689-011-9085-4

Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11689-011-9085-4

Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11689-011-9085-4

The influence of environmental and genetic factors on behavior problems and autistic symptoms in boys and girls with fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11689-011-9085-4

Functional neuroanatomy of visuospatial working memory in fragile X syndrome: relation to behavioral and molecular measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11689-011-9085-4

National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11689-011-9085-4

Memory skills of boys with fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11689-011-9085-4

Effects of methylphenidate treatment in children with mental retardation and ADHD: individual variation in medication response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11689-011-9085-4

Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11689-011-9085-4

Expanding the role of the genetic counselor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11689-011-9085-4

ADHD symptoms in children with FXS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11689-011-9085-4

Electroencephalogram and heart rate regulation to familiar and unfamiliar people in children with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11689-011-9085-4

Effects of video placement and spatial context presentation on path reconstruction tasks with contextualized videos

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11689-011-9085-4

Synaptic synthesis of the Fragile X protein: possible involvement in synapse maturation and elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11689-011-9085-4

Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Psychiatric disorders associated with fragile X in the young female.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Diagnostic accuracy of the Child Behavior Checklist scales for attention-deficit hyperactivity disorder: a receiver-operating characteristic analysis.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Specification of the neurobehavioral phenotype in males with fragile X syndrome.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

Optimal stimulation: a model of disordered activity and performance in normal and deviant children.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261280

A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys

25 September 2018

1 reference

12 December 2020

Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys

1 reference

12 December 2020

Tremor and ataxia in fragile X premutation carriers: Blinded videotape study

1 reference

12 December 2020

A controlled trial of stimulant medication in children with the fragile X syndrome

1 reference

12 December 2020

Cardiovascular indices of physiological arousal in boys with fragile X syndrome

1 reference

12 December 2020

Four-year follow-up of children with low intelligence and ADHD

1 reference

12 December 2020

10.1007/S11689-011-9085-4

Identifiers

DOI

1 reference

9 August 2017

1 reference

9 August 2017

1 reference